1. Home
  2. LYRA vs ANY Comparison

LYRA vs ANY Comparison

Compare LYRA & ANY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • ANY
  • Stock Information
  • Founded
  • LYRA 2005
  • ANY N/A
  • Country
  • LYRA United States
  • ANY United States
  • Employees
  • LYRA N/A
  • ANY 4
  • Industry
  • LYRA Medical/Dental Instruments
  • ANY Finance: Consumer Services
  • Sector
  • LYRA Health Care
  • ANY Finance
  • Exchange
  • LYRA Nasdaq
  • ANY Nasdaq
  • Market Cap
  • LYRA 15.0M
  • ANY 16.4M
  • IPO Year
  • LYRA 2020
  • ANY N/A
  • Fundamental
  • Price
  • LYRA $7.05
  • ANY $0.58
  • Analyst Decision
  • LYRA Buy
  • ANY Strong Buy
  • Analyst Count
  • LYRA 2
  • ANY 1
  • Target Price
  • LYRA $16.00
  • ANY $3.00
  • AVG Volume (30 Days)
  • LYRA 28.3K
  • ANY 1.2M
  • Earning Date
  • LYRA 08-12-2025
  • ANY 08-05-2025
  • Dividend Yield
  • LYRA N/A
  • ANY N/A
  • EPS Growth
  • LYRA N/A
  • ANY N/A
  • EPS
  • LYRA N/A
  • ANY N/A
  • Revenue
  • LYRA $770,000.00
  • ANY $10,831,000.00
  • Revenue This Year
  • LYRA N/A
  • ANY N/A
  • Revenue Next Year
  • LYRA $139.18
  • ANY $12.16
  • P/E Ratio
  • LYRA N/A
  • ANY N/A
  • Revenue Growth
  • LYRA N/A
  • ANY N/A
  • 52 Week Low
  • LYRA $3.81
  • ANY $0.36
  • 52 Week High
  • LYRA $37.50
  • ANY $1.90
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 41.94
  • ANY 48.99
  • Support Level
  • LYRA $6.51
  • ANY $0.46
  • Resistance Level
  • LYRA $7.57
  • ANY $0.61
  • Average True Range (ATR)
  • LYRA 0.55
  • ANY 0.05
  • MACD
  • LYRA 0.14
  • ANY 0.01
  • Stochastic Oscillator
  • LYRA 47.71
  • ANY 70.53

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About ANY Sphere 3D Corp.

Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.

Share on Social Networks: